| HLT |
Report |
Adjusted Diluted EPS (Q2 2026) |
BEAT |
pred ~$2.32 vs. cons $2.28 |
MEDIUM |
| HLT |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$3.38B vs. cons $3.36B |
MEDIUM |
| HLT |
Report |
System-wide RevPAR growth, FXN (Q2 2026) |
BEAT |
pred ~2.9% vs. cons 2.5% |
MEDIUM |
| HLT |
Guide |
FY2026 System-wide RevPAR growth guidance |
BETTER |
guide ~2.5%-3.5% (mid ~3.0%) vs. cons ~2.5% (FY2026) |
MEDIUM |
| HLT |
Guide |
FY2026 Adjusted EBITDA guidance |
BETTER |
guide ~$3.78B vs. cons ~$3.72B (FY2026) |
LOW |
| HLT |
Guide |
Q3 2026 System-wide RevPAR growth commentary |
BETTER |
guide ~3.0%-3.5% vs. cons ~2.8% (Q3 2026), reflecting easing Middle East drag |
LOW |
| HLT |
Guide |
2026 Capital Return Target |
UNCHANGED |
guide ~$3.5B vs. cons ~$3.5B (FY2026) |
HIGH |
| HLT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.3% |
— |
MEDIUM |
| HLT |
Return |
5-day cumulative residual |
+0.4% (FADE) |
A modest EPS/RevPAR beat and a raised FY RevPAR/EBITDA guide should drive an initial positive pop, but with HLT already trading near 33x forward EPS (well above the ~21x industry multiple) and travel/leisure stocks broadly underperforming over the past month on macro/AI-capex/rate anxieties, the magnitude of upside surprise (guide raise likely modest, ~0.3-0.5pt on RevPAR) is unlikely to be large enough to justify further multiple expansion. Any lingering Middle East uncertainty (conflict paused but not resolved) and only in-line revenue also caps follow-through, so the initial reaction should partially fade over the next few sessions as algorithmic/analyst estimate revisions normalize rather than compound. |
MEDIUM |